WHO recommends monoclonal antibodies for ‘high risk’ Covid patients

These high-risk patients include those with non-severe Covid-19 at high risk of hospitalization and also seronegative patients with severe or critical Covid-19. Experts have also cautioned that new variants may diminish the effect of casirivimab and imdevimab.